Thermo Fisher Scientific enables our customers to make the world healthier, cleaner and safer.
Employees: 10001+
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Grayhawk C... | grayhawkca... |
Mentions in press and media 8
| Date | Title | Description |
| 20.05.2024 | Syngulon and ULB announce the issuance by the USPTO of a first joint patent covering an antibiotic-free selection technology | Syngulon and ULB announce the issuance by the USPTO on March 19, 2024 of US Patent 11,932,672 covering an antibiotic-free selection technology based on bacteriocin/immunity for the production of recombinant protein or pDNA. SERAING, Belgium... |
| 01.06.2012 | 3-D cell culture startup gets $725K to market drug discovery products | Three-dimensional cell growth products better mimic the structure and cell-cell and cell-matrix interactions of the in-vivo environment than traditional 2-D surfaces do, but industry has been slow to adopt tools for 3-D cell growth, the com... |
| 11.07.2007 | Coda Genomics: Better proteins through engineering | Coda Genomics, a Laguna Hills, Calif., biotechnology company founded in 2005, concentrates on a thorny but little-realized challenge in biotechnology: Genetic engineering is easy. Protein manufacture is hard. The biotech industry was founde... |
| 12.04.2007 | Avista Capital Partners completes acquisition Of Bioreliance Corporation from Invitrogen Corporation | New York, NY, April 12, 2007 – Avista Capital Partners, a leading private equity firm, announced today it has completed its acquisition of BioReliance Corporation, a business unit of Invitrogen Corporation (NASDAQ: IVGN) for approximately $... |
| 03.04.2007 | Chinks in the stem-cell monopoly | (Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.) The U.S. patent office has invalidated some key stem-ce... |
| 03.04.2007 | Chinks in the stem-cell monopoly | The U.S. patent office has invalidated some key stem-cell patents, a significant move that could shake up a potentially huge market for embryonic stem-cell therapies that may one day restore all kinds of body parts for the sick and injured.... |
| 13.02.2007 | Avista Capital Partners agrees to acquire Bioreliance Corporation for approximately $210 million | New York, NY, February 13, 2007 – Avista Capital Partners, a leading private equity firm, announced today it has signed a definitive agreement to acquire BioReliance Corporation, a business unit of Invitrogen Corporation (NASDAQ: IVGN) for ... |
| - | 3-D cell culture startup gets $725K to market drug discovery products | A startup developing and marketing 3-D cell culture plates and scaffolds for use in drug discovery, cancer research and biotesting is raising money and scaling up its distribution. 3D Biomatrix Inc. launched its Perfecta3D Hanging Drop Plat... |